Effectiveness and Safety of Apixaban Dabigatran and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation

机译：阿哌沙班达比加群和利伐沙班对华法林对虚弱的非瓣膜性心房颤动患者的有效性和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundFrailty predicts poorer outcomes and decreased anticoagulation use in patients with nonvalvular atrial fibrillation. We sought to assess the effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in frail nonvalvular atrial fibrillation patients.

机译：背景脆弱预测非瓣膜性房颤患者的预后较差，抗凝药物的使用减少。我们试图评估阿哌沙班，达比加群和利伐沙班与华法林相比对脆弱的非瓣膜性房颤患者的有效性和安全性。

著录项

期刊名称 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
作者
Brandon K. Martinez; Nitesh A. Sood; Thomas J. Bunz; Craig I. Coleman;
展开▼
作者单位

展开▼
年(卷),期 2018(7),8
年度 2018
页码 e008643
总页数 10
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
anticoagulants atrial fibrillation direct‐acting oral anticoagulants frailty warfarin;

机译：抗凝药;房颤;直接作用的口服抗凝药;体弱;华法林;

相似文献

外文文献
中文文献
专利

1. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack [J] . Coleman Craig I., Peacock W. Frank, Bunz Thomas J., Stroke: A Journal of Cerebral Circulation . 2017,第8期

机译：Apixaban，Dabigatran和Rivaroxaban与非衰弱性心房颤动患者的有效性和安全性和前卒中或瞬态缺血攻击
2. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation [J] . PinkJ., PirmohamedM., HughesD.A. Clinical Pharmacology and Therapeutics . 2013,第2期

机译：达比加群，利伐沙班，阿哌沙班和华法林在非瓣膜性房颤患者治疗中的比较有效性
3. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups [J] . Antonio Gomez-Outes, Ana Isabel Terleira-Fernez, Gonzalo Calvo-Rojas, Thrombosis . 2013,第Null期

机译：达比加群，利伐沙班或阿哌沙班与华法林在非瓣膜性心房颤动患者中的应用：亚组的系统评价和荟萃分析
4. Warfarin Underuse for Nonvalvular Atriai Fibrillation: How to Adjust Our Aims? [C] . G. DI PASQUALE, E. CERE, A. LOMBARDI International Workshop on Cardiac Arrhythmias . 2004

机译：Warfarin Filluse for Nonvalular Atriai颤动：如何调整我们的目标？
5. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for the prevention of stroke prophylaxis in atrial fibrillation. [D] . Harrington, Amanda. 2012

机译：阿哌沙班，达比加群，利伐沙班和华法林预防房颤预防中风的成本效益。
6. Effectiveness and Safety of Dabigatran Rivaroxaban and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation [O] . Xiaoxi Yao, Neena S. Abraham, Lindsey R. Sangaralingham, 2016

机译：达比加群利伐沙班和阿哌沙班对华法林在非瓣膜性心房颤动中的有效性和安全性
7. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation [O] . Brandon K. Martinez, Nitesh A. Sood, Thomas J. Bunz, 2018

机译：Apixaban，Dabigatran和Rivaroxaban与非衰弱性患者的患者对非血管性心房颤动的效果和安全性

Effectiveness and Safety of Apixaban Dabigatran and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation

摘要

著录项

相似文献

相关主题

期刊订阅